Cat. No. ARG0036
Tmem176b Knockout 4T1 is a CRISPR/Cas9-edited mouse mammary carcinoma cell line generated in the aggressive 4T1 triple-negative breast cancer background. TMEM176B is an endolysosomal/Golgi-associated transmembrane protein that regulates vesicular ion homeostasis, NLRP3 inflammasome-related signaling, and antigen processing pathways involving CASP1, IL1B, and IL18. In the highly metastatic 4T1 model, Tmem176b disruption supports studies of tumor immunology, metastasis, inflammatory signaling, and antigen presentation. Typical applications include RT-qPCR, western blotting, ELISA for IL-1??/IL-18, flow cytometry, confocal imaging, immune co-culture assays, and in vivo syngeneic tumor studies.
| Host Cell | 4T1 |
| Morphology | Epithelial-like |
| Age | Unknown |
| Gene Name | Tmem176b |
| Gene Identifier | NCBI Gene ID 65963 |
| Temperature | 37°C |
| Atmosphere | 5% CO₂ |
| Sterility testing | Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination. |
| Mycoplasma testing | Negative for mycoplasma through PCR analysis |
| Pathogens | Cells tested negative for HIV-1, HBV, and HCV. |
Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.
This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.
The Tmem176b Knockout 4T1 Cell Line is a CRISPR/Cas9-engineered mouse mammary carcinoma model in which the Tmem176b gene has been disrupted to eliminate functional gene expression. This stable edited cell line provides an in vitro system for investigating TMEM176B-dependent mechanisms in tumor cells with aggressive biological behavior. Derived in the 4T1 background, the model is particularly relevant for studies of breast cancer, innate immune signaling, vesicular homeostasis, and tumor?Cimmune crosstalk in a syngeneic murine setting.
4T1 is a well-established BALB/c-derived mammary tumor cell line widely used as a model of triple-negative breast cancer with high tumorigenic and metastatic potential. The line is valued for its ability to recapitulate key features of aggressive breast cancer, including rapid primary tumor growth, dissemination, and complex interactions with the immune microenvironment. Because 4T1 cells are frequently used in metastasis, immune-oncology, and host-tumor interaction studies, they provide a biologically relevant context in which to assess how loss of a vesicular membrane regulator alters tumor-intrinsic and immune-modulatory phenotypes.
TMEM176B is an intracellular transmembrane protein associated with endolysosomal and Golgi-related membranes, where it contributes to vesicular ion balance and endolysosomal function. It is regulated by pro-inflammatory stimuli, interferon signaling, TLR agonists, tumor microenvironment stress, and differentiation state, and it has been linked to pathways controlling NLRP3 inflammasome output and antigen presentation. Mechanistically, TMEM176B interacts functionally with TMEM176A, endolysosomal membrane components, and vesicular trafficking regulators, and acts in a pathway connected to NLRP3, PYCARD/ASC, CASP1, IL1B, IL18, ATP6V1 proton pump components, and MHC class I antigen presentation machinery. Through these relationships, TMEM176B can influence caspase-1 activation state, IL1B and IL18 maturation and secretion, inflammasome-dependent cytokine output, and antigen presentation efficiency.
In the 4T1 setting, Tmem176b loss offers a useful model for dissecting how endolysosomal ion regulation intersects with inflammatory signaling and tumor progression. Because 4T1 cells are commonly used to study metastasis and tumor-immune interactions, disruption of Tmem176b can support investigation of how altered vesicular trafficking, inflammasome regulation, and antigen processing contribute to changes in immune cell activation status, tumor-associated inflammatory responses, and metastatic behavior.
This knockout cell line is suitable for pathway-focused studies using western blotting, RT-qPCR, and RNA-seq to profile gene-expression and signaling changes associated with inflammasome and antigen-presentation pathways. Functional characterization may include ELISA-based measurement of IL-1?? and IL-18 secretion, caspase-1 activation assays, flow cytometry analysis of antigen-presentation markers, immunofluorescence or confocal colocalization with endosome-lysosome markers, and co-immunoprecipitation studies of inflammasome-associated machinery. In cancer biology workflows, the model can be applied to migration and invasion assays, apoptosis analyses, immune cell co-culture experiments, and in vivo tumor growth or metastasis studies in syngeneic mice to evaluate TMEM176B-dependent contributions to tumor immunology and therapeutic target assessment. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.
